公司資料
Xilio Therapeutics 股價、新聞與催化劑
- 股票代碼:
- XLO
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
9.49 USD (+3.49%)
收盤價
最後更新: 2026年8月17日
53.9M USD
市值
股價為何變動
As of Aug 17, 2026, XLO closed up 3.49% at $9.49. No new same-company headline was identified in the current news window.
公司概覽
Tumor-Activated Immunotherapy
Xilio Therapeutics engineers cytokines, antibodies, and T-cell engagers that remain masked until activated within the tumor microenvironment.
XTX501
XTX501 combines PD-1 blockade with a masked IL-2 mechanism and is intended as a potential combination backbone across solid tumors.
Masked T-Cell Engagers
Earlier programs include XTX601 targeting CLDN18.2 and a multispecific engager targeting PSMA and STEAP1.
未來催化劑
- An IND submission for XTX501 is planned around mid-2026.
- A Phase 1 study of XTX501 is expected to begin in the second half of 2026.
- Initial Phase 1 data in metastatic non-small cell lung cancer are expected in the second half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。